DOCSLIB.ORG

Special Isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Special Isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ Tuesday 6th - Thursday 8th October 2020 (12.00-16.00 GMT daily) Programme Tuesday 6 October 12:00-12:05 Welcome Alan Hay, Francis Crick Institute, London, UK & Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA 12:05-12:20 Opening Remarks Jeremy Farrar, Wellcome Trust, London, UK 12:20-14:05 Session 1 (Plenary) Co-Chairs: Bin Cao, China-Japan Friendship Hospital, Beijing, China & Maria Zambon, PHE, London, UK 12:20-12:45 COVID-19 Clinical Spectrum, Complications and Coinfections Bin Cao, China-Japan Friendship Hospital, Beijing, China 12:45-13:05 Viral Replication Kinetics and Antibody Responses Malik Peiris, University of Hong Kong, HK SAR, China 13:05-13:25 COVID-19 Autopsy Findings Xiuwu Bian, Third Military Medical University, Chongqing, China 13:25-13:45 Immunopathogenesis of COVID-19 Peter Openshaw, Imperial College London, UK 13:45-14:05 Pathogenesis and Management of ARDS – Richard Wunderink, Northwestern University, Evanston, IL, USA 14:05-14:15 Comfort Break Page 1 of 5 Tuesday 6 October Continued.. 14:15-15:50 Session 2 (Oral Abstract Session 1) Co-Chairs: John Beigel, NIAID, Bethesda, MD, USA & Alan Hay, Francis Crick Institute, London, UK Sofosbuvir and Daclatasvir Compared to Standard of Care in the 14:20-14:35 Treatment of Patients with Coronavirus Infection (COVID-19): A Randomised Controlled Trial - Andrew Hill, University of Liverpool, Liverpool, UK Inhibition of Sirtuins is broadly effective against coronaviruses 14:35-14:50 Liudi Tang, Evrys Bio, LLC, Doylestown, PA, USA Safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) 14:50-15:05 for the treatment of patients with confirmed SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, pilot trial - Tom Wilkinson, University of Southampton, Southampton, UK 15.05-15.20 Repurposing of clinically-approved drugs for the treatment of COVID-19 - Kris White, Icahn School of Medicine at Mount Sinai, New York, NY, USA 15.20-15.35 Safety and Tolerability of Lanadelumab, a Plasma Kallikrein Inhibitor, in Subjects Hospitalized With COVID-19-Related Pneumonia: Phase 1b Study Design - Dan Sexton, Takeda Pharmaceutical Company Ltd, Lexington, MA, USA 15.35-15.50 Fluvoxamine for prevention of clinical deterioration in early COVID-19: results from a randomized placebo-controlled trial Angela M Reiersen, Washington University School of Medicine, St. Louis, MO, USA 15:50-15:55 Close of Day 1 Poster Viewing Page 2 of 5 Wednesday 7 October 12:00-13:50 Session 3 (Plenary) Co-Chairs: Michael Ison, Northwestern University, Evanston, IL, USA & Hui-Ling Yen, University of Hong Kong, HK SAR, China 12:05-12:25 SARS-CoV-2 Antiviral Targets Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA 12:25-12:45 Pre-clinical Models for Downselecting Candidates Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France Convalescent Plasma and Polyclonal Antibodies 12:45-13:05 Michael Joyner, Mayo Clinic, Rochester, MN, USA Monoclonal Antibodies 13:05-13:25 Erica Saphire, La Jolla Institute for Immunology, CA, USA RECOVERY Trial and Strategies for Rapid Clinical Testing 13:25-13:50 Peter Horby, University of Oxford, Oxford, UK 13:50-14:00 Comfort Break 14:00-15:35 Session 4 (Oral Abstract Session 2) Co-Chairs: Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France & Erica Saphire, La Jolla Institute for Immunology, CA, USA 14:05-14:20 Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition - Allison Greaney, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 14:20-14:35 Blockage of Cathepsin L Activity by SLV213, a Novel Cysteine Protease Inhibitor, Prevents SARS-CoV-2 Viral Entry Felix Frueh, Selva Therapeutics, San Diego, CA, USA Effect of JAK inhibitor treatment on clinical outcome, lung 14:35-14:50 pathology, and viral load in a mouse model of pathogenic SARS- CoV-2 infection - Victoria Baxter, University of North Carolina at Chapel Hill, NC, USA Page 3 of 5 Treatment of Severe COVID-19 with Low-Dose Selinexor: 14:50-15:05 Demonstration of Anti-Viral and Anti-Inflammatory Activities in a Randomized, International, Multicenter, Placebo-Controlled Phase 2 Clinical Trial - George Geils, Roper St Francis Healthcare, Charleston, SC, USA 15:05-15:20 Marginal effect of GC-376 as a SARS-CoV-2 antiviral in the K18 hACE2 transgenic Mouse Model - C. Joaquin Caceres, University of Georgia, Athens, Georgia, USA 15:20-15:35 A Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19) - Harish Seethamraju, Montefiore Medical Center, Bronx, NY, USA 15:35-15:40 Close of Day 2 Poster Viewing Page 4 of 5 Thursday 8 October 12:00-12:45 Session 5 (Plenary) Co-Chairs: Kim Armstrong, BARDA, Washington DC, USA & Frederick Hayden, , University of Virginia School of Medicine, Charlottesville, VA, USA 12:00-12:20 Lessons from MERS – Yaseen Arabi, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia 12:20-12:45 Solidarity Trial & Lessons Learned Marie-Pierre Preziosi, WHO, Geneva, Switzerland 12:45-14:10 Session 6 (Clinical Trials Updates) Co-Chairs: Kim Armstrong, BARDA, Washington DC, USA & Frederick Hayden, , University of Virginia School of Medicine, Charlottesville, VA, USA 12:45-12:50 Introduction 12:50-13:05 Remdesivir - Anu Osinusi, Gilead, Foster City, CA, USA 13:05-13:20 EIDD-2801 - Wendy Painter, Ridgeback Biotherapeutics LP, Miami, FL, USA 13:20-13:35 Favipirivir – Yohei Doi, University of Pittsburgh, PA, USA 13:35-13:50 JAK Inhibitors - John Beigel, NIAID, Bethesda, MD, USA 13:50-14:05 Tocilizumab – Larry Tsai, Genentech, S. San Francisco, CA, USA 14:05-14:10 Summary 14:10-14:20 Comfort Break 14:20-15:30 Session 7 (Plenary) Co-Chairs: Michael Ison, Northwestern University, Evanston, IL, USA & Marco Cavaleri, European Medicines Agency, Amsterdam, Netherlands 14:20-14:45 Operation Warp Speed Therapeutics Development Janet Woodcock, CDER, FDA, Washington DC, USA 14:45-15:05 Discussion on Clinical Trial Endpoints – moderated by Michael Ison, Northwestern University, Evanston, IL, USA & Marco Cavaleri, European Medicines Agency, Amsterdam, Netherlands 15:05-15:30 WHO Update on COVID-19 Clinical Management Janet Diaz, WHO, Geneva, Switzerland 15:30-15:45 Close of Conference Page 5 of 5 .
Load more

Recommended publications
  • Tropism of Influenza B Viruses in Human Respiratory Tract Explants and Airway Organoids
    Early View Original article Tropism of influenza B viruses in human respiratory tract explants and airway organoids Christine H.T. Bui, Mandy M.T. Ng, M.C. Cheung, Ka-chun Ng, Megan P.K. Chan, Louisa L.Y. Chan, Joanne H.M. Fong, J.M. Nicholls, J.S. Malik Peiris, Renee W.Y. Chan, Michael C.W. Chan Please cite this article as: Bui CHT, Ng MMT, Cheung MC, et al. Tropism of influenza B viruses in human respiratory tract explants and airway organoids. Eur Respir J 2019; in press (https://doi.org/10.1183/13993003.00008-2019). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2019 Tropism of influenza B viruses in human respiratory tract explants and airway organoids Christine HT Bui1, Mandy MT Ng1, MC Cheung1, Ka-chun Ng1, Megan PK Chan1, Louisa LY Chan1,3, Joanne HM Fong1, JM Nicholls2, JS Malik Peiris1, Renee WY Chan3#, Michael CW Chan1# 1School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China 2Department of Pathology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China 3Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China #Correspondence to: Michael C.W.
    [Show full text]
  • Regulation of Host Immune Responses Against Influenza a Virus Infection by Mitogen-Activated Protein Kinases (Mapks)
    microorganisms Review Regulation of Host Immune Responses against Influenza A Virus Infection by Mitogen-Activated Protein Kinases (MAPKs) Jiabo Yu 1, Xiang Sun 1, Jian Yi Gerald Goie 2,3 and Yongliang Zhang 2,3,* 1 Integrative Biomedical Sciences Programme, University of Edinburgh Institute, Zhejiang University, International Campus Zhejiang University, Haining 314400, China; [email protected] (J.Y.); [email protected] (X.S.) 2 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore; [email protected] 3 The Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore * Correspondence: [email protected]; Tel.: +65-65166407 Received: 18 June 2020; Accepted: 15 July 2020; Published: 17 July 2020 Abstract: Influenza is a major respiratory viral disease caused by infections from the influenza A virus (IAV) that persists across various seasonal outbreaks globally each year. Host immune response is a key factor determining disease severity of influenza infection, presenting an attractive target for the development of novel therapies for treatments. Among the multiple signal transduction pathways regulating the host immune activation and function in response to IAVinfections, the mitogen-activated protein kinase (MAPK) pathways are important signalling axes, downstream of various pattern recognition receptors (PRRs), activated by IAVs that regulate various cellular processes in immune cells of both innate and adaptive immunity. Moreover, aberrant MAPK activation underpins overexuberant production of inflammatory mediators, promoting the development of the “cytokine storm”, a characteristic of severe respiratory viral diseases. Therefore, elucidation of the regulatory roles of MAPK in immune responses against IAVs is not only essential for understanding the pathogenesis of severe influenza, but also critical for developing MAPK-dependent therapies for treatment of respiratory viral diseases.
    [Show full text]
  • News in Brief
    The world this week News in brief PUBLISHERS UNITE TO TACKLE ALTERED IMAGES The world’s largest science publishers are teaming up to establish standards for catching suspicious images in research papers. A new working group — the first formal cross-industry initiative to discuss the issue CORONAVIRUS — aims to set standards for software that screens papers HINDERS AUTOPSIES, for altered or duplicated images DEPRIVING RESEARCH during peer review. OF CRUCIAL TISSUE Journal editors have long been concerned about how As researchers worldwide best to spot altered images, struggle to understand which can result from honest COVID-19’s effects on the body, mistakes or efforts to improve they are clamouring for tissue DOGS CAUGHT CORONAVIRUS FROM THEIR the appearance of images, as samples from patients. But the well as from misconduct. So far, raging pandemic and ongoing OWNERS, GENETIC ANALYSIS SUGGESTS most journals haven’t employed lockdowns have complicated image-checkers to screen efforts to do autopsies and The first two dogs reported at Utrecht University in the manuscripts, saying that it is too collect the tissue needed to to have coronavirus probably Netherlands. In the study, only expensive or time-consuming; understand how the coronavirus caught the infection from 2 of the 15 dogs who lived with and software that can screen attacks organs including the their owners, say researchers infected people got the disease. papers on a large scale hasn’t lungs, heart and brain. who studied the animals and Since the infections in the been available. Autopsies are always members of the infected two canines in Hong Kong — a The new cross-publisher painstaking work, but the households in Hong Kong.
    [Show full text]
  • SMA News Aug'06 CR14.Indd
    34 N e w s News in Brief “This has the potential for doing to the US healthcare system what the Japanese auto industry did to American carmakers.” - Princeton healthcare economist Uwe Reinhardt, on the impact of medical outsourcing. OUTSOURCING YOUR HEART Bumrungrad Hospital in Bangkok, with its marble floors, liveried bellhops, fountains and restaurants, resembles a grand hotel more than a clinic. Described as a mecca of medical trade, Incidentally, Trehan plans to launch his vision it is attracting hordes of medical tourists, a large of the “Mayo Clinic of the East” next year, in the percentage of which now hails from the United form of a $250 million specialty Escorts hospital States (US). complex near Delhi featuring luxury suites, a hotel US hospitals could certainly do with a little and swank restaurants. global competition. For years, their share of the However, there are those who may balk at national healthcare bill has grown at a rate far travelling across the world for a procedure, especially faster than inflation, and today they gobble up a to developing nations like India, where children pick third of all medical expenditures. At current rates, through garbage just outside the hospital doors. the US will be spending $1 of every $5 of its GDP And good luck to the litigious-minded – India’s on healthcare by 2015, yet more than one in four malpractice laws limit damage rewards, one of many workers will be uninsured. reasons healthcare is significantly cheaper. With more American insurance companies and self-insured major corporations taking (Source: Time Magazine) a serious look at medical outsourcing, Asian countries which offer high-quality care at cut-rate VACCINE AGAINST WEIGHT GAIN? prices – for example, Thailand, India, Malaysia A group led by Kim Janda at the Scripps Research and Singapore – are being offered to clients and Institute reports that a vaccination approach may employees, sometimes with the added incentive of be used to treat obesity.
    [Show full text]
  • Virology, Transmission, and Pathogenesis of SARS-Cov-2
    PRACTICE BMJ: first published as 10.1136/bmj.m3862 on 23 October 2020. Downloaded from 1 Division of Infection and Global CLINICAL UPDATE Health Research, School of Medicine, University of St Andrews, St Andrews, UK Virology, transmission, and pathogenesis of SARS-CoV-2 2 Specialist Virology Laboratory, Royal Muge Cevik, 1 , 2 Krutika Kuppalli, 3 Jason Kindrachuk, 4 Malik Peiris5 Infirmary of Edinburgh, Edinburgh, UK and Regional Infectious Diseases Unit, What you need to know viral response phase and an inflammatory second Western General Hospital, Edinburgh, phase. Most clinical presentations are mild, and the UK • SARS-CoV-2 is genetically similar to SARS-CoV-1, but typical pattern of covid-19 more resembles an 3 Division of Infectious Diseases, characteristics of SARS-CoV-2—eg, structural influenza-like illness—which includes fever, cough, Medical University of South Carolina, differences in its surface proteins and viral load malaise, myalgia, headache, and taste and smell Charleston, SC, USA kinetics—may help explain its enhanced rate of disturbance—rather than severe pneumonia transmission 4 Laboratory of Emerging and (although emerging evidence about long term Re-Emerging Viruses, Department of • In the respiratory tract, peak SARS-CoV-2 load is consequences is yet to be understood in detail).1 In Medical Microbiology, University of observed at the time of symptom onset or in the first this review, we provide a broad update on the Manitoba, Winnipeg, MB, Canada week of illness, with subsequent decline thereafter, emerging understanding of SARS-CoV-2 indicating the highest infectiousness potential just 5 School of Public Health, LKS Faculty pathophysiology, including virology, transmission before or within the first five days of symptom onset of Medicine, The University of Hong dynamics, and the immune response to the virus.
    [Show full text]
  • Pathogen Host Interactions: Proteomics of Influenza NEP During Infection Reveals an Antagonistic Role in the Formation of Tight Junctions
    Pathogen host interactions: proteomics of Influenza NEP during infection reveals an antagonistic role in the formation of tight junctions Garrett Robert Poshusta A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: John Aitchison, Chair Wilhelmus Hol Kenneth Stuart Program Authorized to Offer Degree: Biochemistry ©Copyright 2015 Garrett Robert Poshusta University of Washington Abstract Pathogen host interactions: proteomics of Influenza NEP during infection reveals an antagonistic role in the formation of tight junctions Garrett Robert Poshusta Chair of the Supervisory Committee: Affiliate Professor John Aitchison Department of Biochemistry Host-pathogen interaction networks are key to understanding the molecular mechanisms driving disease and can provide new targets for therapeutic intervention. We discovered new host factors interacting with the influenza nuclear export protein (NEP) using an engineered influenza virus expressing NEP with an N-terminal 3xFLAG tag. We collected immunopurification mass spectrometry data for 3xFLAG-NEP during an active infection and during plasmid expression in HEK293T cells. Network analysis of these complementary datasets revealed an enrichment of tight junction proteins in the NEP interactome. Expression of NEP in MDCK cells results in inhibition of tight junction formation as measured by transepithelial electrical resistance and inulin diffusion across the polarized cell monolayer. These findings reveal
    [Show full text]
  • Virology, Transmission, and Pathogenesis of SARS-Cov-2
    PRACTICE BMJ: first published as 10.1136/bmj.m3862 on 23 October 2020. Downloaded from 1 Division of Infection and Global CLINICAL UPDATE Health Research, School of Medicine, University of St Andrews, St Andrews, UK Virology, transmission, and pathogenesis of SARS-CoV-2 2 Specialist Virology Laboratory, Royal Muge Cevik, 1 , 2 Krutika Kuppalli, 3 Jason Kindrachuk, 4 Malik Peiris5 Infirmary of Edinburgh, Edinburgh, UK and Regional Infectious Diseases Unit, What you need to know viral response phase and an inflammatory second Western General Hospital, Edinburgh, phase. Most clinical presentations are mild, and the UK • SARS-CoV-2 is genetically similar to SARS-CoV-1, but typical pattern of covid-19 more resembles an 3 Division of Infectious Diseases, characteristics of SARS-CoV-2—eg, structural influenza-like illness—which includes fever, cough, Medical University of South Carolina, differences in its surface proteins and viral load malaise, myalgia, headache, and taste and smell Charleston, SC, USA kinetics—may help explain its enhanced rate of disturbance—rather than severe pneumonia transmission 4 Laboratory of Emerging and (although emerging evidence about long term Re-Emerging Viruses, Department of • In the respiratory tract, peak SARS-CoV-2 load is consequences is yet to be understood in detail).1 In Medical Microbiology, University of observed at the time of symptom onset or in the first this review, we provide a broad update on the Manitoba, Winnipeg, MB, Canada week of illness, with subsequent decline thereafter emerging understanding of SARS-CoV-2 indicating the highest infectiousness potential just 5 School of Public Health, LKS Faculty pathophysiology, including virology, transmission before or within the first five days of symptom onset of Medicine, The University of Hong dynamics, and the immune response to the virus.
    [Show full text]
  • Serologic Responses in Healthy Adult with SARS-Cov-2 Reinfection
    RESEARCH LETTERS Acknowledgments 8. Kandeil A, Gomaa M, Shehata M, El-Taweel A, Kayed AE, We thank Jesse Gallagher, Melinda Vonkungthong, Anne Abiadh A, et al. Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. Hurley-Bacon, Jasmina Luczo, James Doster, and Charles Emerg Microbes Infect. 2019;8:103–8. https://doi.org/ Foley for technical assistance with this work. 10.1080/22221751.2018.1560235 9. Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu Severe acute respiratory syndrome coronavirus 2, isolate LY, Li M, et al. Middle East respiratory syndrome (MERS) USA-WA1/2020, NR-52281 was deposited by the Centers coronavirus seroprevalence in domestic livestock in Saudi for Disease Control and Prevention and obtained through Arabia, 2010 to 2013. Euro Surveill. 2013;18:20659. BEI Resources, NIAID, NIH. Middle East respiratory https://doi.org/10.2807/1560-7917.ES2013.18.50.20659 10. Barr IG, Rynehart C, Whitney P, Druce J. SARS-CoV-2 does syndrome coronavirus, Florida/USA-2_Saudi Arabia_ not replicate in embryonated hen’s eggs or in MDCK cell 2014, NR-50415 was obtained through BEI Resources, lines. Euro Surveill. 2020;25. https://doi.org/10.2807/ NIAID, NIH. Vero African green monkey kidney cells 1560-7917.ES.2020.25.25.2001122 (ATCC CCL-81), FR-243, were obtained through the International Reagent Resource, Influenza Division, WHO Address for correspondence: Erica Spackman, US National Poultry Collaborating Center for Surveillance, Epidemiology and Research Center, USDA Agricultural Research Service, 934 Station Control of Influenza, Centers for Disease Control and Rd, Athens, GA 30605, USA; email: [email protected] Prevention, Atlanta, GA, USA.
    [Show full text]
  • Phenotypic and Genetic Characterization of MERS Coronaviruses from Africa to Understand Their Zoonotic Potential
    Phenotypic and genetic characterization of MERS coronaviruses from Africa to understand their zoonotic potential Ziqi Zhoua,1, Kenrie P. Y. Huia,1, Ray T. Y. Sob, Huibin Lvb, Ranawaka A. P. M. Pereraa, Daniel K. W. Chua, Esayas Gelayec, Harry Oyasd, Obadiah Njagid, Takele Abaynehc, Wilson Kuriad, Elias Waleligne, Rinah Wangliaf, Ihab El Masryg, Sophie Von Dobschuetzg, Wantanee Kalpravidhg, Véronique Chevalierh,i, Eve Miguelj,k, Ouafaa Fassi-Fihril, Amadou Trarorem, Weiwen Liangb, Yanqun Wangn, John M. Nichollso, Jincun Zhaon, Michael C. W. Chana, Leo L. M. Poona,b, Chris Ka Pun Mokb,p,2, and Malik Peirisa,b,2 aSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China; bHKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China; cNational Veterinary Institute, Debre Zeit, Ethiopia; dDirectorate of Veterinary Services, Nairobi, Kenya; eFood and Agriculture Organization, Emergency Centre for Transboundary Animal Diseases, Addis Ababa, Ethiopia; fFood and Agriculture Organization, Emergency Centre for Transboundary Animal Diseases, Nairobi, Kenya; gFood and Agriculture Organization of the United Nations, Rome 00153, Italy; hCentre de Coopération Internationale en Recherche Agronomique pour le Développement, UMR Animal, Health, Territories, Risk, Ecosystems (ASTRE) Animal, Santé, Territoires, Risques et Ecosystèmes,
    [Show full text]
  • Annual Report – 2019
    1. ANNUAL GENERAL MEETING 2018 The Annual General Meeting of the Sri Lanka Medical Association (SLMA) was held on the 21st December 2018 at 7.00 p.m. at the Lionel Memorial Auditorium, Wijerama House, Colombo 07. Dr. Ruvaiz Haniffa chaired the meeting. He thanked the members of the Council, members of the SLMA and the staff of the SLMA office for their contributions towards making the activities of the SLMA a success. He summarised the achievements and shortcomings during his period of presidency. The Honarary Secretary Dr. Hasini Banneheke tabled the Annual Report 2018 and the minutes of the previous Annual General Meeting held on 15th December 2017. The minutes were unanimously confirmed by the membership present. Dr. Hasini Banneheke thanked the president, the members of the council, members of the SLMA and the staff of the SLMA office for the support given during the year 2018. ELECTION OF OFFICE BEARERS The following Office Bearers and Council Members were unanimously elected. President Dr. Anula Wijesundere President Elect Prof. Indika Karunathilake Vice Presidents Dr. Panduka Karunanayake Dr. Kirthi Gunasekera Secretary Dr. Kapila Jayaratne Assistant Secretaries Dr. Thathya de Silva Dr. Amaya Ellawala Dr. E. A. Sajith T. Edirisinghe Dr. S. D. Samarasekera Treasurer Dr. Yasas Abeywickrama Assistant Treasurer Dr. Pamod Amarakoon Public Relations Officer Dr. Kalyani Guruge Social Secretaries Dr. Christo Fernando Dr. Pramilla Senanayake Past President Representative Retired Professor Wilfred Perera Co-editors, Ceylon Medical Journal Professor A. Pathmeswaran Professor Senaka Rajapakse ELECTED COUNCIL MEMBERS Dr. Iyanthi Abeyewickreme, Dr. Duminda Ariyaratne, Dr. Naomali Amarasena, Dr. Sarath Gamini de Silva, Professor Vajira H.W.
    [Show full text]
  • Is the Cure Worse Than the Disease?
    IS THE CURE WORSE THAN THE DISEASE? REFLECTIONS ON COVID GOVERNANCE IN SRI LANKA EDITED BY PRADEEP PEIRIS 5 Ethno-centric pandemic governance: The Muslim community in Sri Lanka’s COVID response Sakina Moinudeen Introduction “Epidemics can potentially create a medical version of the Hobbesian nightmare – the war of all against all.” (Strong, 1990, p. 258) This strange sense of ‘epidemic psychology’ portrays the situation as posing an immediate threat, either actual or potential, to public order. This was quite evident in the context of the pandemic in Sri Lanka, wherein the state’s ethnocratic1 system of governance (Balasundaram, 2016) was directed towards the Muslim community in particular, in the form of undue scrutiny, stigmatisation, and discrimination. “Classically associated with this epidemic of irrationality, fear and suspicion, there comes close in its train an epidemic stigmatisation both of those with the disease and of those who belong to what are feared to be the main carrier groups. This can begin with avoidance, segregation and abuse… 1 ‘Ethnocracy’ refers to a system of governance run largely based on ethnic calculations; this could be at elections, in policy making, or when handling emergencies. 112 Ethno-centric pandemic governance Personal fear may be translated into collective witch-hunts.” (Ibid, p. 253) This sense of ‘othering’ was widely prevalent throughout the pandemic from contact tracing to the disposal of those deceased of COVID-19 who were of Islamic faith, which not only helped with diverting the public’s attention from the government’s inefficiency in managing the crisis, but also helped to reinforce and even intensify existing prejudices against the Muslim community for mere political advantage.
    [Show full text]
  • A New Pandemic
    http://doi.org/10.4038/sljm.v29i1.172 Sri Lanka Journal of Medicine Vol. 29 No.1, 2020 Sri Lanka Journal of Medicine SLJM Editorial Research COVID-19: A New Pandemic J.S. Malik Peiris Correspondence: J.S. Malik Peiris School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong School of Public Health, Li Ka Shing Faculty of Medicine, Special Administrative Region, China. The University of Hong Kong, Hong Kong Special Administrative Region, E mail: [email protected] China. ORCiD ID: https://orcid.org/0000-0001-8217-5995 In November-December 2019, a novel respiratory The main modes of transmission are infected disease emerged in Wuhan China, which rapidly respiratory droplets and fomites. Coughing, sneezing spread within China and then spread globally to cause or even breathing, can generate infected respiratory the most severe pandemic to afflict humans for at least droplets which may travel a few meters and may deposit on the eyes, nose or mouth of a susceptible Within 5 months (as of 31st of May 2020) it has caused individual, leading to transmission of disease. The over 6 million confirmed cases and over 360,000 virus is known to remain viable on smooth surfaces deaths. Countries with major international air-travel (stainless steel, glass, plastic) for many days and hubs (i.e. Europe and North America) were affected therefore hands touching such contaminated surfaces early but no continent or country is likely to be spared may transfer the virus to the nose, eyes or mouth.5 in the months ahead.
    [Show full text]